The economic impact, healthcare resource utilization, and clinical outcome over 24 months in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Greece- the fidelity study
{{output}}
Background: The review of healthcare costs in multiple sclerosis (MS) has been of increased interest. In this study, we aimed to estimate the economic burden of MS patients, treated with dimethyl fumarate (DMF) in Greece. ... ...
